The in vitro pulmonary vascular effects of FK409 (nitric oxide donor): A study in normotensive and pulmonary hypertensive rats

British Journal of Pharmacology

Volumn 121, Issue 2, 1997, Pages 280-286

  Wanstall, Janet C ^a   Kaye, Jacqueline A ^a   Gambino, Agatha ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

FK409; Hypoxia; Intralobar pulmonary artery; Main pulmonary artery; Nitric oxide donor; Pulmonary hypertension; Reactive oxygen species

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 4 ETHYL 2 HYDROXYIMINO 5 NITRO 3 HEXENAMIDE; CATALASE; METHYLENE BLUE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY DILATATION; ARTERY TONE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; HYPOXIA; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; VASCULAR ENDOTHELIUM;

EID: 0030933589     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701105     Document Type: Article

References (39)

1. ADKINS, W.K. & TAYLOR, A.E. (1990). Role of xanthine oxidase and neutrophils in ischaemia-reperfusion injury in rabbit lung. J. Appl. Physiol., 69, 2012-2018.
2. ARCHER, S.L., HUANG, J.M.C., HAMPL, V., NELSON, D.P., SCHULTZ, P.J. & WEIR, E.K. (1994). Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc. Natl. Acad. Sci. U.S.A., 91, 7583-7587.
3. ARCHER, S.L., HUANG, J.M.C., REEVE, H.L., HAMPL, V., TOLAROVA, S., MICHELAKIS, E. & WEIR, E.K. (1996). Differential distribution of electrophysiologically distinct myocytes in conduit and resistance arteries determines their response to nitric oxide and hypoxia. Circ. Res., 78, 431-442.
4. BOLOTINA, V.M., NAJIBI, S., PALACINO, J.J., PAGANO, P.J. & COHEN, R.A. (1994). Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature, 368, 850-853.
5. CELERMAJER, D.S., CULLEN, S. & DEANFIELD, J.E. (1993). Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation, 87, 440-446.
6. CRAWLEY, D.E., ZHAO, L., GIEMBYCZ, M.A., LIU, S., BARNES, P.J., WINTER, R.J.D. & EVANS, T.W. (1992). Chronic hypoxia impairs soluble guanylyl cyclase-mediated pulmonary arterial relaxation in the rat. Am J. Physiol., 263, L325-L332.
7. DINH-XUAN, A.T. (1993). Disorders of endothelium-dependent relaxation in pulmonary disease. Circulation. 87 (Suppl. V), V81-87.
8. DINH-XUAN, A.T., HIGENBOTTAM, T.W., CLELLAND, C.A., PEPKEZABA, J., CREMONA, G., BUTT, A.Y., LARGE, S.R., WELLS, F.C. & WALLWORK, J. (1991). Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N. Engl. J. Med., 324, 1539-1547.
9. FEELISCH, M., OSTROWSKI, J. & NOACK, E. (1989). On the mechanism of NO release from sydnonimines. J. Cardiovasc. Pharmacol., 14 (Suppl. 11), S13-S22.
10. GAMBINO, A., THOMAS, B.J. & WANSTALL, J.C. (1995). KRN2391 (a combined nitric oxide donor and potassium channel opener) on main and intralobar pulmonary arteries from rats. Proc. Aust. Soc. Clin. Exp. Pharmacol. Toxicol., 2, 84.
11. GHODSI, F. & WILL, J.A. (1981). Changes in pulmonary structure and function induced by monocrotaline intoxication. Am. J. Physiol., 240, H149-H155.
12. HINO, M., IWAMI, M., OKAMOTO, M., YOSHIDA, K., HARUTA, H., OKUHARA, M., HOSODA, J., KOHSAKA, M., AOKI, H. & IMANAKA, H. (1989). FK409, a novel vasodilator isolated from the acid-treated fermentation broth of Streptomyces griseosporeus. 1. Taxonomy, fermentation, isolation and physico-chemical and biological characteristics. J. Antibiotics., 42, 1578-1592.
13. ISONO, T., KOIBUCHI, Y., SATA, N., FURUICHI, A., NISHII, M., YAMAMOTO, T., MORI, J., KOHSAKA, M. & OHTSUKA, M. (1993). Vasorelaxant mechanism of the new vasodilator, FK409. Eur. J. Pharmacol., 246, 205-212.
14. KAYE, J.A. & WANSTALL, J.C. (1995). Vasorelaxant properties of the nitric oxide donor, FK409, in pulmonary arteries from control and pulmonary hypertensive rats. Proc. Aust. Soc. Clin. Exp. Pharmacol. Toxicol., 2, 85.
15. KELM, M. & YOSHIDA, K. (1996). Metabolic fate of nitric oxide and related N-oxides. In Methods in Nitric Oxide Research. ed. Feelisch, M. & Stamler, J.S. pp. 47-58, Chichester: Wiley.
16. KINSELLA, J.P., NEISH, S.R., SHAFFER, E. & ABMAN, S.H. (1992). Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet, 340, 819-820.
17. KITA, Y., HIRASAWA, Y., MAEDA, K., NISHIO, M. & YOSHIDA, K. (1994). Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409. Eur. J. Pharmacol., 257, 123-130.
18. LEFER, A.M. (1993). Why nitric oxide donors? J Cardiovasc. Pharmacol., 22 (Suppl. 7), v-vi.
19. MARCZIN, N., RYAN, U.S. & CATRAVAS, J.D. (1992). Effects of oxidant stress on endothelium-derived relaxing factor-induced and nitrovasodilator-induced cGMP accumulation in vascular cells in culture. Circ. Res., 70, 326-240.
20. MARUYAMA, J. & MARUYAMA, K. (1994). Impaired nitric oxide-dependent responses and their recovery in hypertensive pulmonary arteries of rats. Am. J. Physiol., 266, H2476-H2488.
21. MUNZEL, T., SAYEGH, H., FREEMAN, B.A., TARPEY, M.M. & HARRISON, D.G. (1995). Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J. Clin. Invest., 95, 187-194.
22. MURPHY, R.A. (1980). Mechanics of vascular smooth muscle. In Handbook of Physiology, the Cardiovascular System. ed. Bohr, D.F., Somlyo, A.P. & Sparks, H.V. Sect. 2, Vol. 2, pp. 325-351. Bethesda, MD: American Physiological Society.
23. OHTSUKA, M., KOIBUCHI, Y., SAKAI, S., SATO, N., ISONO, T., ONO, T., MORI, J. & SHIBAYAMA, F. (1990). Cardiovascular activity of FK409, a new drug for ischaemic heart diseases, on dog in vitro and in vivo preparations. Eur. J. Pharmacol., 183/4, 1292-1293.
24. PEPKE-ZABA, J., HIGENBOTTAM, T.W., DINH-XUAN, A.T., STONE, D. & WALLWORK, J. (1991). Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet, 338, 1173-1174.
25. ROBERTS, J.D., POLANER, D.M., LANG, P. & ZAPOL, W.M. (1992). Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet, 340, 818-819.
26. + channel-mediated relaxation. Am. J. Physiol., 263, L88-L94.
27. RUBANYI, G.M. & VANHOUTTE, P.M. (1986). Oxygen-derived free radicals, endothelium, and responsiveness of vascular smooth muscle. Am. J. Physiol., 250, H815-H821.
28. SHIBATA, S., SATAKE, N., SATA, N., MATSUO, M., KOIBUCHI, Y. & HESTER, R.K. (1991). Characteristics of the vasorelaxing action of (3E)-4-ethyl-2-hydroximino-5-nitro-3-hexamide FK409, a new vasodilator isolated from microbial sources, in isolated rabbit arteries. J. Cardiovasc. Pharmacol., 17, 508-518.
29. + current in rat pulmonary artery muscle cells. Am. J. Physiol., 266, H365-H370.
30. SUZUKI, H. & TWAROG, B.M. (1982). Membrane properties of smooth muscle cells in pulmonary hypertensive rats. Am. J. Physiol., 242, H907-H915.
31. TWAROG, B.M. (1988). Pathogenesis of pulmonary hypertension in the rat model. Chest, 93, 100S-101S.
32. WANSTALL, J.C. (1994). In vitro hypoxia attenuates vasorelaxation by potassium channel opening drugs and nitroprusside in isolated pulmonary arteries from rats. J. Pharmacol. Exp. Ther., 271, 845-851.
33. WANSTALL, J.C. & CRILLEY, T.K. (1996). Relaxation of rat pulmonary artery by adrenomedullin involves endothelium-derived nitric oxide and is attenuated in hypoxic pulmonary hypertension. Pharmacol. Commun., 7, 349-357.
34. WANSTALL, J.C., HUGHES, I.E. & O'DONNELL, S.R. (1992). Reduced relaxant potency of nitroprusside on pulmonary artery preparations taken from rats during the development of hypoxic pulmonary hypertension. Br. J. Pharmacol., 107, 407-413.
35. WANSTALL, J.C., HUGHES, I.E. & O'DONNELL, S.R. (1995a). Evidence that nitric oxide from the endothelium attenuates inherent tone in isolated pulmonary arteries from rats with hypoxic pulmonary hypertension. Br. J. Pharmacol., 114, 109-114.
36. WANSTALL, J.C. & O'DONNELL, S.R. (1992). Responses to vasodilator drugs on pulmonary artery preparations from pulmonary hypertensive rats. Br. J. Pharmacol., 105, 152-158.
37. WANSTALL, J.C., THOMAS, B.J. & GAMBINO, A. (1995b). Vasorelaxation by nitric oxide donor drugs on pulmonary arteries from pulmonary hypertensive rats. Br. J. Pharmacol., 116, 61P.
38. WILLIAMSON, D.J., HAYWARD, C., ROGERS, P., WALLMAN, L.L., STURGESS, A.D., PENNY, R. & MACDONALD, P.S. (1996). Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension. Circulation, 94, 477-492.
39. YAMADA, H., YONEYAMA, F., SATOH, K. & TAIRA, N. (1991). Comparison of the effects of the novel vasodilator FK409 with those of nitroglycerin in isolated coronary artery of the dog. Br. J. Pharmacol., 103, 1713-1718.